- Home
- ECBK vs SGMO Comparison
ECBK vs SGMO Comparison
Compare ECBK & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | SGMO |
|---|---|---|
| Founded | 1919 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 155.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ECBK | SGMO |
|---|---|---|
| Price | $17.25 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.60 |
| AVG Volume (30 Days) | 10.9K | ★ 4.0M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.95 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | $29,860,000.00 | ★ $32,875,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.56 | ★ N/A |
| Revenue Growth | ★ 20.84 | N/A |
| 52 Week Low | $12.56 | $0.38 |
| 52 Week High | $17.75 | $1.40 |
Technical Indicators
Market Signals| Indicator | ECBK | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 48.86 |
| Support Level | $17.25 | $0.43 |
| Resistance Level | $17.39 | $0.48 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 40.93 | 60.65 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.